Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F-652 in Alcoholic Hepatitis
NCT02655510Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Feb 2016
- Primary completion
- Jun 2018
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of eflepedocokin alfa in alcoholic hepatitis (AH), sponsored by Mayo Clinic. Started Feb 2016; status: completed.
02
Drugs
eflepedocokin alfa
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT02655510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02655510.